兴齐眼药12月18日获融资买入2699.12万元，融资余额11.82亿元

Core Viewpoint - The financial performance and trading activity of Xingqi Eye Pharmaceutical Co., Ltd. indicate a strong growth trajectory, with significant increases in revenue and net profit, alongside notable trading metrics in the financing and securities lending markets [1][2]. Group 1: Financial Performance - For the period from January to September 2025, Xingqi Eye achieved operating revenue of 1.904 billion yuan, representing a year-on-year growth of 32.27% [2]. - The net profit attributable to shareholders for the same period was 599 million yuan, reflecting a substantial year-on-year increase of 105.98% [2]. - Since its A-share listing, the company has distributed a total of 1.166 billion yuan in dividends, with 985 million yuan distributed over the past three years [2]. Group 2: Trading Activity - On December 18, 2023, Xingqi Eye's stock price fell by 0.69%, with a trading volume of 231 million yuan [1]. - The financing buy-in amount for the same day was 26.99 million yuan, while the financing repayment was 28.31 million yuan, resulting in a net financing outflow of 1.32 million yuan [1]. - As of December 18, 2023, the total balance of margin trading and securities lending for Xingqi Eye was 1.187 billion yuan, with the financing balance accounting for 7.09% of the circulating market value, indicating a high level compared to the past year [1]. Group 3: Shareholder and Institutional Holdings - As of September 30, 2025, the number of shareholders for Xingqi Eye was 54,100, an increase of 16.85% from the previous period [2]. - The average number of circulating shares per shareholder was 3,480, which decreased by 14.42% compared to the previous period [2]. - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited was the second-largest, holding 7.1264 million shares, an increase of 3.6284 million shares from the previous period [2].